FI970298A0 - DHA:n käyttö farmaseuttisena koostumuksena - Google Patents

DHA:n käyttö farmaseuttisena koostumuksena

Info

Publication number
FI970298A0
FI970298A0 FI970298A FI970298A FI970298A0 FI 970298 A0 FI970298 A0 FI 970298A0 FI 970298 A FI970298 A FI 970298A FI 970298 A FI970298 A FI 970298A FI 970298 A0 FI970298 A0 FI 970298A0
Authority
FI
Finland
Prior art keywords
pct
dha
pharmaceutical composition
sec
fatty acids
Prior art date
Application number
FI970298A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970298A (fi
Inventor
Barbara Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of FI970298A0 publication Critical patent/FI970298A0/fi
Publication of FI970298A publication Critical patent/FI970298A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cephalosporin Compounds (AREA)
FI970298A 1995-05-25 1997-01-24 DHA:n käyttö farmaseuttisena koostumuksena FI970298A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment
PCT/GB1996/001265 WO1996037200A1 (en) 1995-05-25 1996-05-24 Use of dha as a pharmaceutical composition

Publications (2)

Publication Number Publication Date
FI970298A0 true FI970298A0 (fi) 1997-01-24
FI970298A FI970298A (fi) 1997-01-24

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970298A FI970298A (fi) 1995-05-25 1997-01-24 DHA:n käyttö farmaseuttisena koostumuksena

Country Status (17)

Country Link
US (1) US6150411A (no)
EP (1) EP0774962B1 (no)
JP (1) JPH10503531A (no)
KR (1) KR970704433A (no)
AT (1) ATE264676T1 (no)
AU (1) AU722474B2 (no)
CA (1) CA2195979A1 (no)
DE (1) DE69632236T2 (no)
DK (1) DK0774962T3 (no)
ES (1) ES2217317T3 (no)
FI (1) FI970298A (no)
GB (1) GB9510636D0 (no)
HK (1) HK1012575A1 (no)
NO (1) NO970317D0 (no)
PT (1) PT774962E (no)
WO (1) WO1996037200A1 (no)
ZA (1) ZA964215B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803451A1 (en) * 1998-10-15 2007-07-04 DSMIP Assets B.V. Pufa supplements
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
CA2493888C (en) 2001-07-27 2013-07-16 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
NO2493478T3 (no) 2009-10-29 2018-07-21
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
MX2018014140A (es) * 2016-06-01 2019-02-25 Nestec Sa Composicion para usar en la profilaxis de enfermedades alergicas.
WO2023102170A1 (en) * 2021-12-02 2023-06-08 The Regents Of The University Of California Compositions and methods for inhibiting seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA

Also Published As

Publication number Publication date
AU722474B2 (en) 2000-08-03
KR970704433A (ko) 1997-09-06
NO970317L (no) 1997-01-24
US6150411A (en) 2000-11-21
DE69632236T2 (de) 2005-04-14
DE69632236D1 (de) 2004-05-27
NO970317D0 (no) 1997-01-24
HK1012575A1 (en) 1999-08-06
AU5827796A (en) 1996-12-11
FI970298A (fi) 1997-01-24
EP0774962B1 (en) 2004-04-21
DK0774962T3 (da) 2004-08-09
ES2217317T3 (es) 2004-11-01
WO1996037200A1 (en) 1996-11-28
ZA964215B (en) 1996-12-04
EP0774962A1 (en) 1997-05-28
JPH10503531A (ja) 1998-03-31
ATE264676T1 (de) 2004-05-15
PT774962E (pt) 2004-09-30
CA2195979A1 (en) 1996-11-28
GB9510636D0 (en) 1995-07-19

Similar Documents

Publication Publication Date Title
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
ID21473A (id) Sediaan farmasi yang mengandung asam eikosapentanoat dan asam stearidonat
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
DE68905863D1 (de) Zusammensetzungen essentieller fettsaeuren.
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
NZ292121A (en) 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl derivatives and pharmaceutical compositions thereof
BG102011A (en) 1,3-propane diol derivatives as bioactive compounds(21) 102012 (22) 31.10.97 (13) l (19) bg (41) 29.05.98 (51) 6c 07 d 209/28 a (51) 6c 07 d 339/04 b (51) 6a 61 k 31/23 b (51) 6c 07 c 69/587 b (51) 6c 07 c 69/767 b (86) pct/gb96/01052,01.05.96 (87) wo96/34855,07.11.96 (31) 9508823 (32) 01.05.95 (33) gb (31) 9517107 (32) 21.08.95 (33) gb (31) 9605440 (32) 15.03.96 (33) gb (71) gb scotia holdings plc (72) gb horrobin, david f. (72) gb manku, mehar (72) gb mcmordie, austin (72) gb knowles, phillip (72) gb redden, peter (72) gb pitt, andrea (74) olga ruseva sirakova, (74) 1124 sofija,kompl."javorov",bl.19,vkh.g (54) fatty acid esters as bioactive compounds
HK37694A (en) Fatty acids compositions
ATE241352T1 (de) Omega-3-fettsäurehaltige zubereitung aus mikroorganismen als prophylaktikum bzw. therapeutikum gegen kokzidiose bei tieren
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
ATE258792T1 (de) Diät mit hohem lipidgehalt
DE69415018D1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
NZ306510A (en) Niacin derivatives which include a fatty acid or fatty acid alcohol residue and their use in medicaments and skin care compositions
ES2124395T3 (es) Utilizacion de esteres de diglicerina contra las impurezas de la piel.
KR0140401B1 (en) Anti-bloom triglyceride compositions
DK0613367T3 (da) Dermatologiske og kosmetiske præparater
ATE175344T1 (de) Gelbildende präparate, die optisch angereicherte gelbildner enthalten
EA200100662A1 (ru) Способ и композиция для поддержания и восстановления целостности кишки
DK0599967T3 (da) Opspaltning af arylalkansyrer.
DK0741579T3 (da) Vandig formulering med forhalet frigivelse
HUP0000419A2 (hu) Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény